Lexaria Bioscience CORP. (LEXX) — SEC Filings

Overview

Lexaria Bioscience CORP. (LEXX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Apr 13, 2026: Lexaria Bioscience Corp. filed its quarterly report (10-Q) on April 13, 2026, for the period ending February 28, 2026. The filing includes financial statements and other disclosures required for public companies. The company's business address is 100 - 740 McCurdy Road, Kelowna, BC V1X 2P7.

Sentiment Summary

Across 46 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 40 neutral, 4 mixed. The dominant filing sentiment for Lexaria Bioscience CORP. is neutral.

Filing Type Overview

Lexaria Bioscience CORP. (LEXX) has filed 7 10-Q, 24 8-K, 3 DEF 14A, 1 S-1/A, 2 10-K, 3 S-1, 2 SC 13G/A, 4 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Recent Filings (46)

• Lexaria Bioscience Files Q1 2026 10-Q — 10-Q · Apr 13, 2026 Risk: medium
  Lexaria Bioscience Corp. filed its quarterly report (10-Q) on April 13, 2026, for the period ending February 28, 2026. The filing includes financial statements
• Lexaria Bioscience Files 8-K on Material Agreement & Equity Sales — 8-K · Dec 16, 2025 Risk: medium
  Lexaria Bioscience Corp. filed an 8-K on December 16, 2025, reporting on events that occurred on December 14, 2025. The filing indicates an entry into a materia
• Lexaria Bioscience Sets Jan 27 Shareholder Meeting; Board, Auditor Votes Loom — DEF 14A · Dec 10, 2025 Risk: low
  Lexaria Bioscience Corp. (LEXX) is holding its 2026 Annual Shareholder Meeting on January 27, 2026, via Event Conferencing, where shareholders will vote on the
• Lexaria Files S-1/A for Resale of 2.76M Shares, Highlights DehydraTECH Progress — S-1/A · Dec 5, 2025 Risk: high
  Lexaria Bioscience Corp. (LEXX) filed an S-1/A on December 5, 2025, for the resale of up to 2,760,000 shares of common stock by selling stockholders, issuable u
• Lexaria Bioscience R&D Surges to $8.2M, Bolstering DehydraTECH Patents — 10-K · Nov 28, 2025 Risk: high
  Lexaria Bioscience Corp. (LEXX) reported an R&D expense of $8.2 million in fiscal 2025, focusing on its patented DehydraTECH drug delivery technology. The compa
• Lexaria Files S-1 for Resale of 2.76M Shares; DehydraTECH Shows Promise — S-1 · Oct 14, 2025 Risk: high
  Lexaria Bioscience Corp. (LEXX) is filing an S-1 to register 2,760,000 shares of common stock for resale by selling stockholders, primarily from warrants issued
• Lexaria Bioscience Files 8-K: Material Agreement, Equity Sales — 8-K · Sep 29, 2025 Risk: medium
  Lexaria Bioscience Corp. filed an 8-K on September 29, 2025, reporting on events as of September 26, 2025. The filing indicates an entry into a material definit
• Lexaria Bioscience Terminates Material Agreement — 8-K · Sep 25, 2025 Risk: medium
  Lexaria Bioscience Corp. filed an 8-K on September 25, 2025, reporting the termination of a material definitive agreement as of September 19, 2025. The filing d
• Lexaria Narrows Q3 Loss Amid Capital Raising Efforts — 10-Q · Jul 14, 2025 Risk: high
  Lexaria Bioscience Corp. reported a net loss of $2,421,983 for the three months ended May 31, 2025, a significant improvement from the $4,520,483 net loss in th
• Lexaria Bioscience Corp. Signs Material Definitive Agreement — 8-K · Jun 12, 2025 Risk: medium
  Lexaria Bioscience Corp. entered into a material definitive agreement on May 14, 2025. The filing does not disclose specific details of the agreement, its count
• Lexaria Bioscience Files 8-K on Material Agreement & Equity Sales — 8-K · Apr 28, 2025 Risk: medium
  Lexaria Bioscience Corp. filed an 8-K on April 28, 2025, reporting on events that occurred on April 24, 2025. The filing indicates an entry into a material defi
• Lexaria Bioscience R&D Surges in Q2 2025 — 10-Q · Apr 14, 2025 Risk: medium
  Lexaria Bioscience Corp. filed its 10-Q for the period ending February 28, 2025. The company reported total assets of $220 million. For the six months ended Feb
• Lexaria Bioscience Corp. Files 8-K with Material Agreement — 8-K · Feb 5, 2025 Risk: medium
  On February 5, 2025, Lexaria Bioscience Corp. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and e
• Lexaria Bioscience Corp. Files 8-K on Shareholder Vote Matters — 8-K · Jan 15, 2025 Risk: low
  Lexaria Bioscience Corp. filed an 8-K on January 15, 2025, reporting on a submission of matters to a vote of security holders. The filing details events that oc
• Lexaria Bioscience Q1 Revenue Drops, Expenses Rise — 10-Q · Jan 10, 2025 Risk: medium
  Lexaria Bioscience Corp. filed its 10-Q for the period ending November 30, 2024. The company reported revenue of $242,198 for the three months ended November 30
• Lexaria Bioscience Corp. Reports Director and Officer Changes — 8-K · Jan 3, 2025 Risk: medium
  Lexaria Bioscience Corp. filed an 8-K on January 3, 2025, reporting changes as of December 31, 2024. The filing covers the departure of directors, election of d
• Lexaria Bioscience Corp. Files Material Definitive Agreement — 8-K · Dec 18, 2024 Risk: medium
  On December 16, 2024, Lexaria Bioscience Corp. entered into a material definitive agreement. The company, incorporated in Nevada with its principal executive of
• Lexaria Bioscience Files Definitive Proxy Statement — DEF 14A · Nov 27, 2024 Risk: low
  Lexaria Bioscience Corp. filed a definitive proxy statement (DEF 14A) on November 27, 2024, for its annual meeting on January 14, 2025. The company, incorporate
• Lexaria Bioscience Files 2024 10-K — 10-K · Nov 26, 2024 Risk: medium
  Lexaria Bioscience Corp. filed its 10-K for the fiscal year ending August 31, 2024. The company, incorporated in Nevada, operates in the pharmaceutical preparat
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Lexaria Bioscience Files 8-K on Shareholder Nominations — 8-K · Oct 18, 2024 Risk: medium
  Lexaria Bioscience Corp. filed an 8-K on October 18, 2024, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing date for this repo
• Lexaria Bioscience Corp. Files 8-K with Material Agreement — 8-K · Oct 16, 2024 Risk: medium
  On October 14, 2024, Lexaria Bioscience Corp. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The com
• Lexaria Bioscience Corp. Reports Director and Officer Changes — 8-K · Oct 2, 2024 Risk: medium
  Lexaria Bioscience Corp. filed an 8-K on October 2, 2024, reporting changes related to its board of directors and officers, as well as compensatory arrangements
• Boos Amends Lexaria Bioscience Stake Filing — SC 13D/A · Sep 23, 2024 Risk: medium
  Wayne W. Boos has amended their Schedule 13D filing for Lexaria Bioscience Corp. as of August 31, 2024. The filing indicates a change in beneficial ownership, t
• Lexaria Bioscience Corp. Files 8-K: Board & Officer Changes — 8-K · Sep 5, 2024 Risk: medium
  Lexaria Bioscience Corp. filed an 8-K on August 31, 2024, reporting changes in its board of directors and executive officers, along with updates on compensatory
• Lexaria Bioscience Corp. Signs Material Definitive Agreement — 8-K · Aug 22, 2024 Risk: medium
  Lexaria Bioscience Corp. announced on August 21, 2024, that it has entered into a material definitive agreement. The company, incorporated in Nevada, filed an 8
• Lexaria Bioscience Corp. 13D/A Filing - Ownership Update — SC 13D/A · Aug 6, 2024 Risk: medium
  On August 6, 2024, Lexaria Bioscience Corp. filed an amendment (No. 3) to its Schedule 13D. This filing relates to the acquisition of common stock by Boos Wayne
• Lexaria Bioscience Corp. Files 8-K: Board Changes & Officer Compensation — 8-K · Jul 17, 2024 Risk: medium
  Lexaria Bioscience Corp. announced on July 15, 2024, a change in its board of directors, including the election of new directors and the appointment of certain
• Lexaria Bioscience Q3 2024: $15.8M Revenue, $8.1M Net Income — 10-Q · Jul 12, 2024 Risk: medium
  Lexaria Bioscience Corp. filed its Q3 2024 10-Q report for the period ending May 31, 2024. The company reported $15.81 million in revenue and $8.09 million in n
• Lexaria Bioscience Files S-1 for Securities Offering — S-1 · Jun 3, 2024 Risk: medium
  Lexaria Bioscience Corp. filed an S-1 form on June 3, 2024, to register securities. The company, incorporated in Nevada, is in the pharmaceutical preparations s
• Lexaria Bioscience Files 8-K for Material Agreement & Equity Sales — 8-K · Apr 30, 2024 Risk: medium
  Lexaria Bioscience Corp. filed an 8-K on April 30, 2024, reporting the entry into a material definitive agreement and unregistered sales of equity securities. T
• Lexaria Bioscience Corp. 13D/A Filing — SC 13D/A · Apr 25, 2024 Risk: medium
  On April 25, 2024, Lexaria Bioscience Corp. filed an amendment (No. 2) to its Schedule 13D. This filing relates to the acquisition of common stock by Boos Wayne
• Lexaria Bioscience Corp. Files 8-K on Shareholder Vote Matters — 8-K · Apr 24, 2024 Risk: medium
  Lexaria Bioscience Corp. filed an 8-K on April 24, 2024, reporting on a submission of matters to a vote of security holders. The filing details information rela
• Lexaria Bioscience Corp. Files 10-Q for Period Ending February 29, 2024 — 10-Q · Apr 9, 2024 Risk:
  Lexaria Bioscience Corp. (LEXX) filed a Quarterly Report (10-Q) with the SEC on April 9, 2024. Revenue for the six months ended February 29, 2024, was $1,238,76
• Lexaria Bioscience Corp. Signs Material Definitive Agreement — 8-K · Mar 21, 2024 Risk: medium
  Lexaria Bioscience Corp. entered into a material definitive agreement on March 15, 2024. The filing does not disclose specific details of the agreement, such as
• Lexaria Bioscience Appoints New CFO — 8-K · Mar 15, 2024 Risk: medium
  Lexaria Bioscience Corp. announced on March 14, 2024, the appointment of Mr. John D. Miller as Chief Financial Officer. Mr. Miller brings extensive financial le
• Lexaria Bioscience Corp. Files Form S-1 for Public Offering — S-1 · Mar 12, 2024 Risk: medium
  Lexaria Bioscience Corp. (LEXX) filed a IPO Registration (S-1) with the SEC on March 12, 2024. Lexaria Bioscience Corp. filed a Form S-1 with the SEC on March 1
• Lexaria Bioscience Corp. Announces 2024 Annual Shareholder Meeting Details — DEF 14A · Mar 6, 2024 Risk: low
  Lexaria Bioscience Corp. (LEXX) filed a Proxy Statement (DEF 14A) with the SEC on March 6, 2024. Lexaria Bioscience Corp. will hold its 2024 annual shareholder
• Lexaria Bioscience Files 8-K — 8-K · Mar 1, 2024 Risk: low
  Lexaria Bioscience Corp. filed an 8-K on February 29, 2024, reporting other events. The filing details the company's incorporation in Nevada and provides its pr
• Lexaria Bioscience Enters Material Agreement, Sells Equity — 8-K · Feb 16, 2024 Risk: medium
  Lexaria Bioscience Corp. entered into a material definitive agreement on February 14, 2024, involving the issuance of equity securities. The company, based in K
• Boos Amends Lexaria Bioscience Ownership Filing — SC 13D/A · Feb 14, 2024 Risk: medium
  Wayne W. Boos filed an Amendment No. 1 to Schedule 13D (SC 13D/A) on February 14, 2024, regarding his beneficial ownership in Lexaria Bioscience Corp. common st
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Lexaria Bioscience Confirms Nasdaq Listing for Common Stock & Warrants — 8-K · Jan 30, 2024
  Lexaria Bioscience Corp. filed an 8-K on January 29, 2024, to report 'Other Events.' This filing confirms the company's registration of its Common Stock and War
• Lexaria Bioscience Confirms Nasdaq Listing for Stock & Warrants — 8-K · Jan 24, 2024
  Lexaria Bioscience Corp. filed an 8-K on January 24, 2024, primarily to disclose its common stock and warrants are registered on The Nasdaq Capital Market under
• Lexaria Bioscience Corp. Files 10-Q for Period Ending November 30, 2023 — 10-Q · Jan 12, 2024 Risk: low
  Lexaria Bioscience Corp. (LEXX) filed a Quarterly Report (10-Q) with the SEC on January 12, 2024. Lexaria Bioscience Corp. reported revenue of $809,165 for the
• Lexaria Bioscience Files 8-K for Regulation FD Disclosure — 8-K · Jan 4, 2024
  Lexaria Bioscience Corp. filed an 8-K on January 4, 2024, primarily for Regulation FD Disclosure and to include Financial Statements and Exhibits. This filing i

Frequently Asked Questions